TheraRadar
← Back
Data updated: Jun 28, 2026

SHENZHEN TECHDOW

Generics

SHENZHEN TECHDOW is a generic drug manufacturer focused on Cardiovascular, Respiratory.

2014
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

SHENZHEN TECHDOW's Key Drugs

SHENZHEN TECHDOW's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SHENZHEN TECHDOW's Recent FDA Approvals

New NDA/BLA approvals for SHENZHEN TECHDOW over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SHENZHEN TECHDOW's Therapeutic Areas

SHENZHEN TECHDOW's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 50%
1 drugs
Respiratory 50%
1 drugs

SHENZHEN TECHDOW's Top Competitors

SHENZHEN TECHDOW's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SHENZHEN TECHDOW Pipeline Snapshot

Active clinical trials for SHENZHEN TECHDOW across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling